• Corpus ID: 32795859

Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro.

  title={Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro.},
  author={Makoto Shimoyama and Masayuki Kawai and S Nasu and K Shioji and Y Hoshi},
  journal={Physiological chemistry and physics},
  volume={7 2},
Inhibition of cAMP phosphodiesterase from rat liver by nicotinamide and its homologues was studied. Among the several compounds tested, such agents as nicotinamide, N2-ethylnicotinamide, N2-methylnicotinamide, N,N-diethylnicotinamide, 3-acetylpyridine, methylnicotinate, and ethylnicotinate showed potent inhibition of cAMP phosphodiesterase, with an over 90% inhibition by 5 mM ethylnicotinate when cAMP was used as substrate at a 0.48 x 10(-7) M concentration. A comparison of the inhibitory… 
Transient downregulation of protein O-N-acetylglucosaminylation by treatment of high-dose nicotinamide in human cells
Nicotinamide at millimolar concentrations affects cell survival in various conditions, and is being utilized therapeutically in many human diseases. However, the effect of an acute treatment of
Inhibitors and activators of ADP-ribosylation reactions
Several potent inhibitors of arginine-specific mono(ADP-ribosyl)transferases and activators of poly(ADp-ribose) synthetase are found.
Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching.
In studies aimed at identifying other signaling pathways that promote switching, it is discovered that inhibitors of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) increase LPS-induced switching to IgA in the B cell lymphoma 1.29 mu and to IgG1 in LPS + IL-4-treated splenic B cells.
Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection
It is proposed that PZA treatment modulates the host immune response to Mtb infection by reducing pro-inflammatory cytokine production, probably through PPAR- and NF-kB- dependent pathways.
A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets
The main immunologic pathways involved in the pathogenesis of bullous pemphigoid are summarized, with an emphasis on the role of eosinophils, immunoglobulins, cytokines such as the interleukin (IL)-4 and IL-5, and complements.